Many companies featured on Money advertise with us. Opinions are our own, but compensation and
in-depth research may determine where and how companies appear. Learn more about how we make money.

Money is not a client of any investment adviser featured on this page. The information provided on this page is for educational purposes only and is not intended as investment advice. Money does not offer advisory services.

Getty Images

The stock market soared Monday after investors learned some very good news about a potential COVID-19 vaccine. But some stocks are faring better than others.

Traders, still digesting the results of the recent U.S. election, woke up to more big news Monday morning: Drug makers Pfizer and BioNTech said the COVID-19 vaccine they recently tested in more than 40,000 subjects had proved 90% effective. Assuming the treatment proves safe, the companies predicted 50 million doses could be available this year — and more than a billion in 2021.

Stock investors — sensing the economy could return to normal as even sooner than hoped — reacted with glee. Shortly after the market opened the Dow surged more 1,200 points, or nearly 4.4%, to 29,563.

Of course, not all companies have struggled as the pandemic upended the way Americans live and spend money. Some had thrived. And as the prospect of a vaccine threw their newfound competitive advantage into question, investors balked. Plenty of shares were down on what, it seems safe to say, is unambiguously good news on the public health front.